Best of BS Opinion: Opportunities galore in the east, Covid crisis & more

Here are the best of Business Standard's opinion pieces for Thursday

India has faltered at multiple levels in the rollout of its vaccination programme. As a result, the pace is much lower than desired. Bharat Biotech, for instance, on Tuesday said the government’s procurement price at Rs 150 per dose for Covaxin was not sustainable in the long run. This effectively means that the firm has little or no incentive to increase production, which can directly affect the vaccine rollout. In this context our lead editorial argues that India’s covid-19 vaccination programme should not suffer because of less-than- adequate planning. Read here
 

Efforts by India to get back Mehul Choksi will